Lifitegrast Crystalline Forms S1 and S2
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing crystalline forms of lifitegrast are difficult to prepare and lack stability, making them unsuitable for large-scale production and pharmaceutical applications.
Innovation Solution
Development of two new crystalline forms (S1 and S2) of lifitegrast characterized by specific powder X-ray diffraction patterns and thermal analysis profiles, which can be prepared through mild reaction conditions and high-yield processes, including dissolution in methanol and precipitation with n-heptane or suspension in water, maintaining stability and preventing conversion to other forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing crystalline forms of lifitegrast are used, then pharmaceutical applications can be pursued, but preparation difficulty increases and stability decreases
Solution Approach 1:
The patent applies parameter changes by modifying crystallization conditions including solvent selection (methanol, n-heptane, water), temperature control (20-30°C dissolution, refrigeration for precipitation), and pH adjustment to generate stable crystalline forms with improved preparation ease. Specifically, dissolving lifitegrast in methanol at 20-30°C followed by addition of n-heptane and refrigeration yields crystalline form S1 with characteristic PXRD peaks, while suspension in water and drying produces crystalline form S2, both exhibiting enhanced stability and manufacturability
Solution Approach 2:
The patent utilizes phase transitions through controlled crystallization processes where lifitegrast transitions from dissolved state to crystalline precipitate. The dissolution-precipitation method involves heating to dissolve, then cooling and adding anti-solvent to induce crystallization. The suspension-drying method involves suspending in water and drying to obtain crystalline forms. These phase transitions enable generation of stable crystalline forms with defined PXRD patterns and improved preparation characteristics
2Productivity
If existing crystalline forms of lifitegrast are used, then pharmaceutical composition development can proceed, but manufacturing scalability is limited
Solution Approach 1:
The patent optimizes crystallization parameters for scalable manufacturing by using common solvents (methanol, n-heptane, water), controlling temperature within standard ranges (20-30°C dissolution, refrigeration for precipitation), and employing simple operational steps (dissolution, addition of anti-solvent, filtration, drying). These parameter changes enable high-yield production of crystalline forms suitable for large-scale pharmaceutical manufacturing
Solution Approach 2:
The crystallization process exhibits self-service characteristics where the system automatically generates crystals through controlled precipitation or suspension-drying without requiring complex intervention. The dissolved lifitegrast spontaneously precipitates upon addition of n-heptane and refrigeration, or forms crystals during water suspension and drying, enabling scalable production with minimal manual operation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new crystalline forms of lifitegrast are stable, easy to produce on a large scale, and exhibit good crystallinity, ensuring consistent quality and high yields, suitable for pharmaceutical use.
Implementation Method 1
dissolving lifitegrast in methanol
Implementation Method 2
adding n-heptane to form a slurry comprising a precipitate
Implementation Method 3
suspending a crystalline form S1 of lifitegrast in water to obtain a suspension comprising a precipitate
Implementation Method 4
drying the precipitate to obtain the crystalline form S1 of lifitegrast
Data Source
AI summary
Crystalline form S1 of lifitegrast characterized by a powder X-ray diffraction pattern with peaks at about 10.7±0.2, 16.2±0.2, 19.9±0.2, 22.1±0.2, 24.7±0.2, and 25.9±0.2 degrees two-theta, crystalline form S2 of lifitegrast characterized by a powder X-ray diffraction pattern with peaks at about 16.4±0.2, 24.9±0.2, and 26.2±0.2 degrees two-theta, and processes of making thereof are provided.